LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $327,823 | +52.7% | 277,816 | +82.5% | 0.00% | – |
Q2 2023 | $214,643 | -53.3% | 152,229 | -50.3% | 0.00% | – |
Q1 2023 | $459,180 | +197.8% | 306,120 | +132.3% | 0.00% | – |
Q4 2022 | $154,197 | +120.3% | 131,793 | +110.7% | 0.00% | – |
Q3 2022 | $70,000 | -65.5% | 62,562 | -51.5% | 0.00% | – |
Q2 2022 | $203,000 | -46.0% | 128,905 | -47.2% | 0.00% | – |
Q1 2022 | $376,000 | -71.0% | 244,155 | -53.8% | 0.00% | – |
Q4 2021 | $1,295,000 | +309.8% | 528,557 | +321.7% | 0.00% | – |
Q3 2021 | $316,000 | -13.9% | 125,343 | -2.7% | 0.00% | – |
Q2 2021 | $367,000 | +41.7% | 128,762 | +16.5% | 0.00% | – |
Q1 2021 | $259,000 | +13.6% | 110,527 | -14.8% | 0.00% | – |
Q4 2020 | $228,000 | +356.0% | 129,670 | +142.9% | 0.00% | – |
Q3 2020 | $50,000 | -31.5% | 53,383 | -36.9% | 0.00% | – |
Q2 2020 | $73,000 | +52.1% | 84,546 | +44.9% | 0.00% | – |
Q1 2020 | $48,000 | -72.6% | 58,348 | -70.4% | 0.00% | – |
Q4 2019 | $175,000 | +130.3% | 197,324 | +152.9% | 0.00% | – |
Q3 2019 | $76,000 | – | 78,022 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |